Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tioga Pharmaceuticals, a developer of novel treatments for gastrointestinal diseases, has received patent number 7,960,42 from the US Patent and Trademark Office (USPTO).
Subscribe to our email newsletter
The new patent entitled, ‘KAPPA-OPIATE AGONISTS FOR THE TREATMENT OF DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME,’ covers the usage of asimadoline in treating diarrhea predominant irritable bowel syndrome (D-IBS).
The patent will expire in June 2028.
Further, Tioga Pharmaceuticals is now organizing a multi-center Phase 3 clinical trial investigating asimadoline in D-IBS under a special protocol assessment (SPA) agreement with the FDA for US registration.
Tioga chief operating officer and general counsel David Urso said this patent augments the extensive asimadoline patent estate and covers the use of asimadoline for the treatment of diarrhea predominant irritable bowel syndrome.
"The patent will provide market exclusivity in the US into June of 2028 and potentially beyond with patent term extension," Urso said.